Tumor necrosis factor-α exerts pro-myogenic action in C2C12 myoblasts via sphingosine kinase/S1P2 signaling  by Donati, Chiara et al.
FEBS Letters 581 (2007) 4384–4388Tumor necrosis factor-a exerts pro-myogenic action in
C2C12 myoblasts via sphingosine kinase/S1P2 signaling
Chiara Donatia,b, Paola Nincheria, Francesca Cencettia,b, Elena Rapizzia,b,
Marta Farnararoa, Paola Brunia,b,*
a Dipartimento di Scienze Biochimiche, Universita` degli Studi di Firenze, Viale G.B. Morgagni 50, 50134 Firenze, Italy
b Istituto Interuniversitario di Miologia (IIM), Universita` degli Studi di Firenze, Viale G.B. Morgagni 50, 50134 Firenze, Italy
Received 25 July 2007; revised 1 August 2007; accepted 3 August 2007
Available online 14 August 2007
Edited by Sandro SonninoAbstract In this study, we report that low doses of tumor necro-
sis factor-a (TNFa) promote myogenesis in C2C12 myoblasts.
Moreover, the cytokine increased sphingosine kinase (SphK)
activity and induced SphK1 translocation to membranes. The
inhibition of SphK functionality by various approaches abro-
gated the pro-myogenic eﬀect of TNFa. Moreover, silencing of
S1P2 impaired the positive action of TNFa on myogenesis. These
results represent the ﬁrst evidence that SphK/S1P2 axis is
required for the regulation of myogenesis by TNFa. In view of
the physiological role of TNFa in muscle regeneration, the pres-
ent ﬁnding reinforces the notion that SphK/S1P2 signaling is
critically implicated in myogenesis.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Skeletal muscle satellite cells are muscle resident, quiescent
stem cells that are critical for myogenesis during development
as well as adult skeletal muscle repair [1]. Among the multitude
of extracellular cues which physiologically modulate satellite
cell biology, the action of tumor necrosis factor-a (TNFa)
appears to be highly complex. TNFa at high doses induces
muscle wasting, essentially by interfering with the ability of
satellite cells to diﬀerentiate into myoﬁbres [2]. Conversely,
TNFa at low doses appears to be physiologically implicated
in the adaptation of muscle in response to exercise and trau-
matic injury, being synthesized by healthy skeletal muscle
where it promotes satellite cell diﬀerentiation [3,4].
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid
that regulates diverse biological processes including cell
growth, survival and diﬀerentiation [5]. We have previously
shown that S1P promotes myogenic diﬀerentiation of C2C12
myoblasts [6]. Moreover, sphingosine kinase (SphK), whichAbbreviations: TNFa, tumor necrosis factor-a; SphK, sphingosine
kinase; S1P, sphingosine 1-phosphate; MHC, myosin heavy chain;
siRNA, short interfering RNA; SKI, sphingosine kinase inhibitor;
WTSphK1, wild-type SphK1; DNSphK1, catalytically inactive SphK1
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doi:10.1016/j.febslet.2007.08.007catalyzes the phosphorylation of sphingosine to S1P, has been
recently found to be required for myogenic diﬀerentiation [7].
Since various studies have demonstrated that SphK is involved
in the signaling pathway of TNFa and in its subsequent bio-
logical response [8–10], the possible involvement of SphK/
S1P signaling in the pro-myogenic eﬀect exerted by low dose
of TNFa has been here investigated.2. Materials and methods
2.1. Materials
Mouse skeletal muscle C2C12 cells were obtained from the Euro-
pean Collection of Cell Cultures (Salisbury, United Kingdom). TNFa
was from PeproTech (London, United Kingdom). Antibodies against
myogenin and S1P2 were obtained from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA). Anti-b-actin antibody was from Cyto-
skeleton Inc., (Denver, CO, USA). Short interfering RNA (siRNA)
duplexes corresponding to two DNA target sequences of mouse
SphK1 (5 0-UAGGAACUGUGGCCUCUAATT-3 0; 5 0-GUGUUAU-
GCAUCUGUUCUATT-3 0), mouse S1P2 (5 0-AAGGTCAAGCTC-
TACGGCAGT-3 0; 5 0-GACUAAUCAGAUUGUAGUATT-3 0) and
scrambled siRNA (5 0-UUCUCCGAACGUGUCACGUTT-3 0) were
obtained from Sigma-Proligo (The Woodlands, TX, USA). Sphingo-
sine Kinase Inhibitor (SKI) [2-(p-hydroxyanilino)-4-(p-chlorophe-
nyl)thiazole] [11] was purchased from Calbiochem (San Diego, CA,
USA). Oligofectamine reagent was purchased from Invitrogen
(Carlsbad, CA, USA). [c-32P] ATP (3000 Ci/mmol) was from Amer-
sham Pharmacia Biotech (Uppsala, Sweden). pcDNA3.1 vectors
encoding for wild-type SphK1 (WTSphK1) and catalytically inactive
SphK1G82D (DNSphK1) [12] were a kind gift of Dr. S. Pitson (Hanson
Institute, Adelaide, Australia). SphK1 antibody was kindly provided
by Dr. Y. Banno (Gifu University Graduate School of Medicine,
Japan).
2.2. Cell culture and transfection
C2C12 myoblasts were grown in DMEM supplemented with 10%
calf serum. For experiments conﬂuent cells were shifted to DMEM
without serum containing 1 mg/ml BSA. Cells stably expressing
WTSphK1 or DNSphK1 were obtained as described previously
[7,13]. To silence SphK1 and S1P2, cells were transfected with speciﬁc
or scrambled siRNA using Oligofectamine reagent according to
manufacturer’s instructions.
2.3. Western blot analysis
Total cell lysates and subcellular fractions were obtained as previ-
ously described [6,14]. Proteins (30 lg) were resolved by SDS–PAGE,
transblotted to PVDF membranes and immunopositive bands visual-
ized by enhanced chemiluminescence.
2.4. SphK activity assay
SphK activity was measured essentially according to Olivera et al.
[15] in cell extracts (60 lg) previously centrifuged at 700 · g forblished by Elsevier B.V. All rights reserved.
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50 lM sphingosine complexed with 4 mg/ml fatty acid free-BSA,
[32P] c-ATP (0.5 lCi, 1 mM) and 10 mM MgCl2 for 30 min at 37 C.
Reactions were terminated by acidic phase separation. After TLC
development, the radioactive spots corresponding to [32P] S1P were
visualized by autoradiography and quantiﬁed. SphK speciﬁc activity
was expressed in pmol/min/mg protein.3. Results
3.1. Bimodal eﬀect of TNFa on C2C12 cell diﬀerentiation
The eﬀect of low amount of TNFa on diﬀerentiation of
C2C12 myoblasts was evaluated by examining the expression
of known myogenic markers. For this purpose, conﬂuent myo-
blasts were serum-starved, treated or not with 0.2 ng/ml TNFa
for various time-intervals and subjected to Western analysis ofFig. 1. Eﬀect of TNFa on myogenic diﬀerentiation of C2C12 cells. (A)
C2C12 myoblasts were incubated with DMEM containing 1 mg/ml
BSA for various time-intervals with or without 0.2 ng/ml TNFa.
Skeletal muscle marker levels were analyzed by Western analysis in cell
lysates. Band intensity, quantiﬁed by densitometric analysis, is
reported as percentage relative to the intensity of the band corre-
sponding to respective control set as 100. Equally loaded protein was
checked by expression of the non-muscle speciﬁc b isoform of actin.
(B) Upper panel: C2C12 cells, were incubated in DMEM containing
1 mg/ml BSA for 24 h with the indicated concentrations of TNFa. Cell
extracts were analyzed to determine the expression of myogenin by
immunoblotting. Lower panel: densitometric analysis of three inde-
pendent experiments. The eﬀect of TNFa was statistically signiﬁcant
by Student’s t-test, (*P < 0.001).myogenin, MHC and caveolin-3. Results presented in Fig. 1A,
clearly indicate that TNFa exerts a pro-myogenic action, being
able to enhance the content of the early myogenic marker
myogenin at 24 and 48 h of incubation as well as that of
MHC at 24 h; however, the late myogenic marker caveolin-3
was not aﬀected by TNFa treatment, indicating that the cyto-
kine can hasten only the early phase of myogenic diﬀerentia-
tion. Interestingly, TNFa did not aﬀect cellular content of
the other membrane adapter, caveolin-1 (data not shown).
The eﬀect of diﬀerent concentrations of TNFa on the expres-
sion of myogenin was then studied. As shown in Fig. 1B, the
cytokine at 1 ng/ml did not inﬂuence the expression of the
myogenic marker, which was instead strongly reduced by
20 ng/ml TNFa.
3.2. The pro-myogenic eﬀect of TNFa is mediated by SphK1
In view of the recognized ability of TNFa to regulate SphK
[8–10] and the pro-myogenic role exerted by S1P and SphK inFig. 2. Eﬀect of TNFa on SphK activity and SphK1 intracellular
localization. (A) Cells were incubated with 0.2 ng/ml TNFa for the
indicated time-intervals, lysed and cell extracts employed for SphK
activity determination. Data represent the means ± S.E.M. of ﬁve
independent experiments performed in duplicate. The eﬀect of TNFa
was statistically signiﬁcant (*P < 0.05; **P < 0.001). (B) Upper panel:
myoblasts were incubated for the indicated time-intervals with or
without 0.2 ng/ml TNFa. Western analysis of SphK1 was performed in
membrane and cytosolic fractions. Lower panel: densitometric analysis
of three independent experiments. Data reported are expressed as fold
increase of membrane:cytosol ratio. The increase of SphK1 membrane
content was statistically signiﬁcant by Student’s t-test, (*P < 0.05;
**P < 0.001).
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then examined. Data illustrated in Fig. 2A show that 0.2 ng/
ml TNFa rapidly and transiently increased SphK activity.
Moreover, as shown in Fig. 2B, myoblast treatment with
0.2 ng/ml TNFa was responsible for sustained SphK1 translo-
cation to membranes. Conversely, cell treatment with 20 ng/mlFig. 3. Involvement of SphK1 in pro-myogenic action of TNFa. (A) Aliquot
or WTSphK1 or DNSphK1 were subjected to Western analysis using anti-
DNSphK1-transfected cells were incubated with 0.2 ng/ml TNFa for 24 h. W
densitometric analysis of three independent experiments. The eﬀect of TNFa
were added with 10 lM SKI 30 min before being administrated with 0.2 ng/m
myogenin. Lower panel: densitometric analysis of three independent experim
Aliquots of control or scrambled- or SphK1-siRNA-treated cells were resolve
Upper panel: control or scrambled or speciﬁc SphK1 siRNA-transfected C2C
cell lysates were separated onto SDS–PAGE and probed with anti-myogeni
experiments. The eﬀect of TNFa was statistically signiﬁcant (*P < 0.001).TNFa did not aﬀect SphK activity or SphK1 subcellular distri-
bution (data not shown).
The possible implication of SphK in the myogenic eﬀect of
TNFa was subsequently investigated. At ﬁrst, C2C12 cells
were transfected with WTSphK1 or DNSphK1. The actual
expression of the protein was veriﬁed by Western analysiss of cell lysates prepared from C2C12 cells expressing the empty vector,
FLAG antibody. (B) Upper panel: control vector- or WTSphK1- or
estern analysis of myogenin was performed in cell lysates. Lower panel:
was statistically signiﬁcant (*P < 0.001). (C) Upper panel: myoblasts
l TNFa for 24 h. Cells lysates were employed for Western analysis of
ents. The eﬀect of TNFa was statistically signiﬁcant (*P < 0.01). (D)
d by SDS–PAGE and immunodetected using anti-SphK1 antibody. (E)
12 cells were treated or not with 0.2 ng/ml TNFa for 24 h. Aliquots of
n antibody. Lower panel: densitometric analysis of three independent
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SphK1 in myoblasts [7], overexpression of SphK1 greatly
increased myogenin content which was not further aug-
mented by TNFa (Fig. 3B). Instead, 0.2 ng/ml TNFa was un-
able to induce the expression of myogenin in cells
overexpressing DNSphK1. Secondly, the pro-myogenic eﬀect
of TNFa was evaluated in C2C12 cells where SphK activity
was pharmacologically inhibited. As shown in Fig. 3C, cell
incubation with 10 lM SKI 30 min prior to TNFa adminis-
tration fully prevented the up-regulation of myogenin exerted
by the cytokine. Thirdly, myoblast SphK1 was down-regu-
lated by siRNA (Fig. 3D). In this experimental condition
the myogenin levels were not enhanced in response to TNFa,
conﬁrming the involvement of SphK in the pro-myogenic
action of TNFa.
3.3. S1P2 is required for the pro-myogenic action of S1P
Finally, since S1P2 was shown to be critical for the pro-
myogenic action of S1P and SphK1 [6,7], its role in the pro-
diﬀerentiating eﬀect of TNFa was also studied. siRNA tech-
nology was utilized to down-regulate S1P2; as shown in
Fig. 4A the membrane content of the receptor was appreciably
diminished after 48 h of speciﬁc siRNA treatment; notably, in
these cells, TNFa was unable to increase myogenin levels
(Fig. 4B).Fig. 4. Eﬀect of S1P2 silencing on the pro-myogenic eﬀect of TNFa.
(A) Control or scrambled- or S1P2-siRNA-treated cells were lysed and
subjected to cell fractionation. Proteins were resolved by SDS–PAGE
and immunodetected using polyclonal anti-S1P2 antibody. (B) Control
or scrambled or speciﬁc S1P2 siRNA-transfected cells were treated or
not with 0.2 ng/ml TNFa for 24 h. Proteins from cell lysates were
subjected to Western analysis of myogenin. Lower panel. Densitomet-
ric analysis of three independent experiments. The eﬀect of TNFa was
statistically signiﬁcant (* at least P < 0.01).4. Discussion
The signaling pathway initiated by the activation of SphK,
the subsequent formation of S1P and its ligation to S1P2,
appears to be critically involved in the regulation of myoblast
diﬀerentiation [6,7]. Here, for the ﬁrst time, evidence is pre-
sented that SphK/S1P2 axis is required for the pro-myogenic
action of TNFa, a cytokine physiologically involved in the reg-
ulation of skeletal muscle diﬀerentiation.
In agreement with a previous report [4], low concentration of
TNFa was found to enhance the early diﬀerentiation of C2C12
myoblasts, being able to increase the expression of the early
myogenic marker myogenin and MHC during the ﬁrst 48 h
of incubation. Conversely, the observed inability of the cyto-
kine to aﬀect the cellular content of caveolin-3, indicates that
late events of myogenic diﬀerentiation are regulated in a
TNFa-independent manner. On the contrary, myoblast chal-
lenge with high concentration of TNFa evoked an anti-myo-
genic response, conﬁrming that TNFa plays a dual role in
skeletal muscle cells [2–4].
Notably, TNFa at low dose provoked a rapid and transient
increase of SphK activity as well as the relocalization of
SphK1 at membranes, which resulted necessary for the pro-
myogenic eﬀect of cytokine. Indeed, when SphK functionality
was impaired by diﬀerent approaches, the TNFa-induced
expression of myogenin was abrogated or strongly reduced.
In contrast, TNFa did not up-regulate myogenin in SphK1-
overexpressing myoblasts. This is likely due to the enhanced
enzymatic activity exhibited by these cells [7], which may be
not further increased by the cytokine.
So far, TNFa-stimulated SphK activity has been shown to
be critical for its antiapoptotic [16] and mitogenic [17] action,
as well as for the inﬂammatory reaction [9,10]. The present
study demonstrates that TNFa signaling via SphK1 is impli-
cated also in the regulation of skeletal muscle diﬀerentiation.
SphK activation has been repeatedly shown to be involved
in the biological response elicited by TNFa in various cell
types, however pioneering studies in the ﬁeld were mainly
focused on the action of S1P as intracellular mediator [8,16].
For this reason the eventual coupling of TNFa-mediated
SphK activation to S1P receptors was not carefully explored.
However, it has been very recently shown that TNFa-stimu-
lated cell proliferation in astrocytoma cells relies on SphK acti-
vation but not on S1P receptor engagement [17], reinforcing
the notion that S1P generated in response to TNFa can actu-
ally regulate biological events acting intracellularly. In con-
trast, in this study the induction of myogenesis by TNFa
was found to be abolished when S1P2 was silenced, consis-
tently with the hypothesis that S1P generated intracellularly
following TNFa challenge, is released outside the cell to trigger
the myogenic response via S1P2. Mechanistically, these results
are in agreement with those obtained in endothelial cells in
which S1P1 and S1P3 were found involved in the TNFa-direc-
ted SphK-dependent activation of nitric oxide synthase [10].
Here, the reported identiﬁcation of SphK/S1P2 axis in the
pro-myogenic eﬀect of TNFa can be relevant from a physio-
logical point of view: it has been recently reported that auto-
crine TNFa is crucially involved in skeletal muscle p38
MAPK activation, master regulator of myogenesis [18]. Since
SphK is required for myogenesis [7], and exogenous S1P is
pro-myogenic via S1P2-dependent activation of p38 MAPK
[6], it is tempting to speculate that SphK/S1P2 axis plays a role
4388 C. Donati et al. / FEBS Letters 581 (2007) 4384–4388in the induction of p38 MAPK by TNFa in skeletal muscle.
This hypothesis is also corroborated by the observed SphK-
dependency of p38 MAPK activation by TNFa in endothelial
cells [19].
In summary, this study adds a new piece of information
about the molecular mechanisms implicated in the regulation
of skeletal muscle diﬀerentiation and further supports the
notion that SphK/S1P signaling represents a key step in this
complex biological process.
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